Breaking News, Collaborations & Alliances

BioArctic, Eisai Ink Research Agreement for BAN2802 in AD

To evaluate potential new treatment combining BioArctic's BrainTransporter technology with an undisclosed Alzheimer drug candidate.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer’s disease.   BioArctic and Eisai have a long-standing collaboration dating back to 2005 for ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters